Report
Jehanne Leroy
EUR 1000.00 Purchase single report

Advicenne - Assemblée générale des actionnaires du 24 mai 2019

Les politique de rémunérations 2019 des dirigeants proposent des hausses des rmunérations fixes que la société n'explique pas.
Par ailleurs, la société n'a pas amélioré sa communication concernant les critères de performance des rémunération s variables. Au regard de l’absence de justification de cette hausse et du manque général d’information dans la politique de rémunération (critères de performance du bonus ou de la rémunération actionnariale, volume de cette dernière etc…), nous ne les soutenons pas.

Concernant les rémunérations attribuées, malgré une transparence là encore plutot faible, les montants en jeu sont modérés et le premier dirigeant, qui détient personnellement 250 000 actions de la société, voit ses intérêts bien liés à la performance de la société. Nous recommandons donc l’approbation. Cependant, des améliorations de communication, notamment concenant les modalités de détermination du bonus annuel seraient appréciables.

Underlying
Advicenne SA

Advicenne SA. ADVICENNE S.A. is a late-stage biopharmaceutical company based in France. The Company focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company's medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.

Provider
Proxinvest
Proxinvest

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Analysts
Jehanne Leroy

Other Reports on these Companies
Other Reports from Proxinvest
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch